During the last decades, therapies that disrupt the tumor endothelium mainly by blocking the vascular endothelial growth factor (VEGF) and its receptors have been approved for the treatment of several advanced cancers, hence validating the initial paradigm [6,7]. The gene discussed is VEGFA; the disease is cancer.